Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Farmers Insurance
McKesson
Harvard Business School
US Army
Covington
Julphar
Queensland Health
Express Scripts
Cipla
Cantor Fitzgerald

Generated: January 23, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 018558

« Back to Dashboard

NDA 018558 describes LITHIUM CARBONATE, which is a drug marketed by Able, Alembic Ltd, Apotex Inc, Glenmark Generics, Hetero Labs Ltd Iii, Mylan Pharms Inc, Usl Pharma, Watson Labs, West-ward Pharms Int, Alembic Pharms Ltd, Barr, Glenmark Pharms Inc, Heritage Pharma, Hikma Intl Pharms, Unique Pharm Labs, Pfizer, and Sun Pharm Inds Inc, and is included in twenty-nine NDAs. It is available from thirty-four suppliers. Additional details are available on the LITHIUM CARBONATE profile page.

The generic ingredient in LITHIUM CARBONATE is lithium carbonate. There are fifteen drug master file entries for this compound. Thirty-five suppliers are listed for this compound. Additional details are available on the lithium carbonate profile page.
Summary for 018558
Tradename:LITHIUM CARBONATE
Applicant:West-ward Pharms Int
Ingredient:lithium carbonate
Patents:0
Therapeutic Class:Bipolar Agents
Formulation / Manufacturing:see details
Pharmacology for NDA: 018558
Medical Subject Heading (MeSH) Categories for 018558
Suppliers and Packaging for NDA: 018558
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
LITHIUM CARBONATE lithium carbonate TABLET;ORAL 018558 NDA West-Ward Pharmaceuticals Corp 0054-4527 0054-4527-31 1000 TABLET in 1 BOTTLE (0054-4527-31)
LITHIUM CARBONATE lithium carbonate TABLET;ORAL 018558 NDA West-Ward Pharmaceuticals Corp 0054-4527 0054-4527-25 100 TABLET in 1 BOTTLE (0054-4527-25)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength300MG
Approval Date:Jan 29, 1982TE:ABRLD:Yes

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKesson
Moodys
US Department of Justice
Cerilliant
Baxter
Chubb
Mallinckrodt
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot